Why undergoing this examination?

Thrombophilia is the tendency to develop clots and occurs as a consequence of changes in the coagulation system. Thrombosis is the main factor responsible for acute myocardial infarction, strokes, and venous thromboembolism (VTE). Its prevalence is over 10%, constituting the first cause of mortality and morbidity in Western society, where this condition may be responsible for about 27% of associated mortality. Thrombophilia, or a predisposition to thrombosis, is a complex condition that involves environmental or acquired factors, genetic factors, and gene-environment interactions. Genetic thrombophilias account for more than half of the cases. 

What is this exam?

The Thrombo InCode test evaluates 12 genetic variants associated with an increased risk of thrombosis development. The result is obtained through a mathematical algorithm that allows the patient’s risk assessment in three ways: the patient’s risk of presenting thrombophilia associated with the current clinical condition (variable factors such as weight, smoking, habits, and lifestyle); the patient’s risk compared to the risk of Factor V Leiden heterozygosity with the same clinical profile; and the risk with the same clinical profile considering the detected genetic variants. This allows for a complete analysis of genetic implications in thrombophilia risk. 

For whom is it indicated?

• Patients with a pattern of VTE or a pathology suggesting a hereditary component: 
• Idiopathic venous thromboembolism under 45 years old; 
• Recurrent venous thrombosis; 
• Venous thrombosis in infrequent vascular territories; 
• Neonatal fulminant purpura; 
• Warfarin-induced skin necrosis; 
• Unexplained arterial thrombosis; 
• Patients at risk for thrombosis factors; 
• High-risk surgeries; 
• Prolonged periods of immobilization; 
• Oral contraceptives, hormone replacement therapy, estrogen therapy. 

Technology

Reverse Transcription Polymerase Chain Reaction (RT-PCR).